MDEA: Difference between revisions

Line 17:

In a 1967 lab notebook entry, Alexander Shulgin briefly mentioned a colleague's report of no effect from the substance with a 100mg dose.<ref>Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin|doi=10.1111/j.1360-0443.2010.02948.x}}</ref> Shulgin later tested the compound at a range of higher doses and characterized the substance in his book [[PiHKAL]].<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref>

MDEA is rarely sold on its own and has historically been used as an occasional additive or substitute ingredient in pills of "Ecstasy". In the United States, MDEA was introduced recreationally in 1985 as a legal substitute to the newly banned MDMA before it was made a Schedule I substance in on August 13, 1987 under the Federal Analog Act.<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref>

MDEA is rarely sold on its own and has historically been used as an occasional additive or substitute ingredient in pills of "Ecstasy", with studies conducted in the 1990s finding MDEA present in approximately four percent of ecstasy tablets.<ref> The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA) | http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00007.x/pdf</ref> In the United States, MDEA was introduced recreationally in 1985 as a legal substitute to the newly banned MDMA before it was made a Schedule I substance in on August 13, 1987 under the Federal Analog Act.<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref>

While MDEA shares many of the ~~same~~ entactogenic properties of MDMA, it is slightly less potent and considered to be more "stoning", lacking the pro-socializing and energizing "magic" most party-goers seek in their MDMA~~/ecstasy~~ experiences. As a result, it is largely considered by most people to be a less desirable variant of MDMA and is thus rarely produced and sold in the illicit drug market, typically showing up in small batches synthesized and distributed by hobbyist clandestine chemists.

While MDEA shares many of the core entactogenic properties of MDMA, it is slightly less potent and considered to be more "stoning", lacking the pro-socializing and energizing "magic" most party-goers seek in their MDMA experiences. As a result, it is largely considered by most people to be a less desirable variant of MDMA and is thus rarely produced and sold in the illicit drug market, typically showing up only in small batches synthesized and distributed by hobbyist clandestine chemists.

==Chemistry==

Line 26:

==Pharmacology==

MDEA has been shown to act as a [[releasing agent]] and [[reuptake inhibitor]] of the key [[monoamine]] [[neurotransmitters]] [[serotonin]], [[dopamine]] and [[noradrenaline]]<ref> The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA) | http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00007.x/pdf}}</ref> which are the [[neurotransmitters]] in charge of pleasure, reward, motivation and focus. This is done by inhibiting the reuptake and reabsorption of [[monoamine neurotransmitter]]s after they have performed their function of transmitting a neural impulse, essentially allowing them to accumulate and be reused in a manner which causes physically stimulating and euphoric effects.<ref>New Insights into the Mechanism of Action of Amphetamines | http://www.annualreviews.org/doi/abs/10.1146/annurev.pharmtox.47.120505.105140</ref> The previously mentioned "stoning" effects have been theorized to arise from the higher relative activity MDEA has on releasing serotonin over dopamine compared to MDMA.

MDEA has been shown to act as a [[releasing agent]] and [[reuptake inhibitor]] of the key [[monoamine]] [[neurotransmitters]] [[serotonin]], [[dopamine]] and [[noradrenaline]]<ref> The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA) | http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00007.x/pdf</ref> which are the [[neurotransmitters]] in charge of pleasure, reward, motivation and focus. This is done by inhibiting the reuptake and reabsorption of [[monoamine neurotransmitter]]s after they have performed their function of transmitting a neural impulse, essentially allowing them to accumulate and be reused in a manner which causes physically stimulating and euphoric effects.<ref>New Insights into the Mechanism of Action of Amphetamines | http://www.annualreviews.org/doi/abs/10.1146/annurev.pharmtox.47.120505.105140</ref> The previously mentioned "stoning" effects have been theorized to arise from the higher relative activity MDEA has on releasing serotonin over dopamine compared to MDMA.

It has also been noted that MDEA, even at lower doses, stimulates the release of oxytocin and prolactin, two hormones that have a role in the feeling of trust and love. <ref> Passie, Torsten, MD. Healing with Entactogens. Santa Cruz: Multidisciplinary Association for Psychedelic Studies, n.d. Print. </ref>

@@ Line 17: / Line 17: @@
 In a 1967 lab notebook entry, Alexander Shulgin briefly mentioned a colleague's report of no effect from the substance with a 100mg dose.<ref>Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin|doi=10.1111/j.1360-0443.2010.02948.x}}</ref> Shulgin later tested the compound at a range of higher doses and characterized the substance in his book [[PiHKAL]].<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref>
-MDEA is rarely sold on its own and has historically been used as an occasional additive or substitute ingredient in pills of "Ecstasy". In the United States, MDEA was introduced recreationally in 1985 as a legal substitute to the newly banned MDMA before it was made a Schedule I substance in on August 13, 1987 under the Federal Analog Act.<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref>
+MDEA is rarely sold on its own and has historically been used as an occasional additive or substitute ingredient in pills of "Ecstasy", with studies conducted in the 1990s finding MDEA present in approximately four percent of ecstasy tablets.<ref> The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA) | http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00007.x/pdf</ref> In the United States, MDEA was introduced recreationally in 1985 as a legal substitute to the newly banned MDMA before it was made a Schedule I substance in on August 13, 1987 under the Federal Analog Act.<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref>
-While MDEA shares many of the same entactogenic properties of MDMA, it is slightly less potent and considered to be more "stoning", lacking the pro-socializing and energizing "magic" most party-goers seek in their MDMA/ecstasy experiences. As a result, it is largely considered by most people to be a less desirable variant of MDMA and is thus rarely produced and sold in the illicit drug market, typically showing up in small batches synthesized and distributed by hobbyist clandestine chemists.
+While MDEA shares many of the core entactogenic properties of MDMA, it is slightly less potent and considered to be more "stoning", lacking the pro-socializing and energizing "magic" most party-goers seek in their MDMA experiences. As a result, it is largely considered by most people to be a less desirable variant of MDMA and is thus rarely produced and sold in the illicit drug market, typically showing up only in small batches synthesized and distributed by hobbyist clandestine chemists.
 ==Chemistry==
@@ Line 26: / Line 26: @@
 ==Pharmacology==
-MDEA has been shown to act as a [[releasing agent]] and [[reuptake inhibitor]] of the key [[monoamine]] [[neurotransmitters]] [[serotonin]], [[dopamine]] and [[noradrenaline]]<ref> The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA) | http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00007.x/pdf}}</ref> which are the [[neurotransmitters]] in charge of pleasure, reward, motivation and focus. This is done by inhibiting the reuptake and reabsorption of [[monoamine neurotransmitter]]s after they have performed their function of transmitting a neural impulse, essentially allowing them to accumulate and be reused in a manner which causes physically stimulating and euphoric effects.<ref>New Insights into the Mechanism of Action of Amphetamines | http://www.annualreviews.org/doi/abs/10.1146/annurev.pharmtox.47.120505.105140</ref> The previously mentioned "stoning" effects have been theorized to arise from the higher relative activity MDEA has on releasing serotonin over dopamine compared to MDMA.
+MDEA has been shown to act as a [[releasing agent]] and [[reuptake inhibitor]] of the key [[monoamine]] [[neurotransmitters]] [[serotonin]], [[dopamine]] and [[noradrenaline]]<ref> The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA) | http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00007.x/pdf</ref> which are the [[neurotransmitters]] in charge of pleasure, reward, motivation and focus. This is done by inhibiting the reuptake and reabsorption of [[monoamine neurotransmitter]]s after they have performed their function of transmitting a neural impulse, essentially allowing them to accumulate and be reused in a manner which causes physically stimulating and euphoric effects.<ref>New Insights into the Mechanism of Action of Amphetamines | http://www.annualreviews.org/doi/abs/10.1146/annurev.pharmtox.47.120505.105140</ref> The previously mentioned "stoning" effects have been theorized to arise from the higher relative activity MDEA has on releasing serotonin over dopamine compared to MDMA.
 It has also been noted that MDEA, even at lower doses, stimulates the release of oxytocin and prolactin, two hormones that have a role in the feeling of trust and love. <ref> Passie, Torsten, MD. Healing with Entactogens. Santa Cruz: Multidisciplinary Association for Psychedelic Studies, n.d. Print. </ref>